Symprove has been shown to inhibit the growth of pathogenic bacteria and promote a healthier gut environment by three independent invitro studies.
The studies found Symprove inhibits the growth of:
One study concluded a reduction in pH and production of metabolites with the use of Symprove, which may be responsible for the pathogen inhibiting results reported.
The studies were carried out at University College London and intestinal research specialists ProDigest in Belgium.
Professor Simon Gaisford of University College London said: “The latest data shows that Symprove has a clear inhibitory effect on pathogens, including C. difficile and MRSA, under lab conditions. This is a powerful first step towards using beneficial live bacteria as part of the management of patients with potentially life-threatening infections.”
Antibiotics are currently the preferred treatment protocol for pathogenic bacteria. However, antibiotics target all gut bacteria, whether pathogenic or not, and change the gut environment. Reinfection is a common problem and further courses of antibiotics are required. These three studies suggest that Symprove could play an important role in the future of pathogen bacteria control in inhibiting the initial bacteria growth as well as having an anti-pathogenic action on established colonies of pathogenic bacteria.
Study 1: In vitro inhibition of Clostridium difficile by commercial probiotics; UCL School of Pharmacy, University College London.
Four commercial probiotic strains and products, including Symprove, were co-cultured with C. difficile and monitored in a microthermal calorimeter - a device that measures the heat produced from growing bacteria. The study found that Symprove had inhibitory activity against C. difficile through altering the pH level in the environment and producing by-product substances that suppressed the growth of C. difficile.
Study 2: Evaluation of the anti-pathogenic activity of Symprove in the human gastrointestinal tract using the SHIME technology platform; ProDigest, Belgium.
A Simulator of the Human Intestinal Microbial Ecosystem (SHIME) was used to re-create the conditions of the human gastrointestinal tract. The model was inoculated with adherent-invasive E. coli (AIEC) along with a microbiota found in the colon and two doses of Symprove were given over 48 hours. The results indicated that Symprove had an anti-pathogenic effect against E.Coli (AIEC).
Study 3: Evaluating the antibacterial activity of Symprove against common pathogens; UCL School of Pharmacy, University College London
A dose of Symprove was mixed with a glucose solution, sterilised meat and E. coli, Shigella sonnei and methicillin-resistant Staphylococcus aureus (MRSA). It was incubated without oxygen and the levels of pathogen bacteria and Symprove were measured at 24 and 48 hours. The results demonstrated that Symprove has an antagonistic effect on E. Coli, Shigella sonnei and MRSA. The researchers noted that the current recommendations for probiotics are as a preventative therapy. But the study suggests there is potential in using Symprove to reduce some pathogenic species in the gut and restore a healthy gut microbiome.
This short video helps to explain how Symprove creates an environment which suppresses pathogenic bacteria.
On September 20, 2017, we presented the results from these three studies to media medics. This video gives an overview of the presentation as well as reaction to the studies.
Symprove will be announcing the results of further studies in the coming months. Please fill out your details to keep up-to-date.
Welcome to Symprove Holdings Limited scientific website.
To access this site, please confirm that you are a healthcare professional, scientist or journalist.